UK markets open in 4 hours 11 minutes
  • NIKKEI 225

    28,641.13
    -181.16 (-0.63%)
     
  • HANG SENG

    29,493.01
    -666.00 (-2.21%)
     
  • CRUDE OIL

    52.50
    -0.27 (-0.51%)
     
  • GOLD FUTURES

    1,859.10
    +3.90 (+0.21%)
     
  • DOW

    30,960.00
    -36.98 (-0.12%)
     
  • BTC-GBP

    23,186.70
    -480.18 (-2.03%)
     
  • CMC Crypto 200

    639.20
    -37.69 (-5.57%)
     
  • ^IXIC

    13,635.99
    +92.93 (+0.69%)
     
  • ^FTAS

    3,752.00
    -34.06 (-0.90%)
     

T-Cell Immunotherapy Market Research Report by Mechanism Of Action, by Product Class, by Type of Therapy, by Indication - Global Forecast to 2025 - Cumulative Impact of COVID-19

ReportLinker
·6-min read

T-Cell Immunotherapy Market Research Report by Mechanism Of Action (Active Immunotherapy and Passive Immunotherapy), by Product Class (Bispecific Antibodies, Cytokines, Monoclonal Antibodies, and Oncolytic Virus Therapy), by Type of Therapy, by Indication - Global Forecast to 2025 - Cumulative Impact of COVID-19

New York, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "T-Cell Immunotherapy Market Research Report by Mechanism Of Action, by Product Class, by Type of Therapy, by Indication - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p06007640/?utm_source=GNW

Market Statistics:
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.

1. The Global T-Cell Immunotherapy Market is expected to grow from USD 4,184.98 Million in 2020 to USD 7,606.66 Million by the end of 2025.
2. The Global T-Cell Immunotherapy Market is expected to grow from EUR 3,669.47 Million in 2020 to EUR 6,669.67 Million by the end of 2025.
3. The Global T-Cell Immunotherapy Market is expected to grow from GBP 3,262.17 Million in 2020 to GBP 5,929.35 Million by the end of 2025.
4. The Global T-Cell Immunotherapy Market is expected to grow from JPY 446,644.26 Million in 2020 to JPY 811,824.22 Million by the end of 2025.
5. The Global T-Cell Immunotherapy Market is expected to grow from AUD 6,077.15 Million in 2020 to AUD 11,045.89 Million by the end of 2025.

Market Segmentation & Coverage:
This research report categorizes the T-Cell Immunotherapy to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Mechanism Of Action, the T-Cell Immunotherapy Market studied across Active Immunotherapy and Passive Immunotherapy.

Based on Product Class, the T-Cell Immunotherapy Market studied across Bispecific Antibodies, Cytokines, Monoclonal Antibodies, and Oncolytic Virus Therapy.

Based on Type of Therapy, the T-Cell Immunotherapy Market studied across CAR-T, TCR, and TIL.

Based on Indication, the T-Cell Immunotherapy Market studied across B-cell Malignancies, Liver Cancer, Prostate Cancer, and Renal Cell Carcinoma.

"The Asia-Pacific is projected to witness the highest growth during the forecast period"

Based on Geography, the T-Cell Immunotherapy Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded the largest size in the T-Cell Immunotherapy Market in 2020. On the other hand, the Asia-Pacific is expected to grow at the fastest CAGR during the forecast period.

Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global T-Cell Immunotherapy Market including Adaptimmune Therapeutics, Apac Biotech, Atara Biotherapeutics, Autolus, Bluebird bio, CARsgen Therapeutics, Cellectis, Chimera Bioengineering, Dendreon Pharmaceuticals LLC, Eureka Therapeutics, Gilead Sciences, Inc., Green Cross Corp, Innovative Cellular Therapeutics, Juno Therapeutics, JW CreaGene Co., Ltd, Kite Pharma, Lava Therapeutics, Lion Biotechnologies, Lyell Immunopharma, Nanjing Legend Pharmaceutical & Chemical, Neogene Therapeutics, NeoTX Therapeutics, Novartis AG, Oxford Vacmedix, Poseida Therapeutics, Sinobioway Cell Therapy, TScan Therapeutics, Xenetic Biosciences, Xyphos, and ZIOPHARM Oncology.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

360iResearch™ FPNV Positioning Matrix:
The 360iResearch™ FPNV Positioning Matrix evaluates and categorizes the vendors in the T-Cell Immunotherapy Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

360iResearch™ Competitive Strategic Window:
The 360iResearch™ Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch™ Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:
1. What is the market size and forecast of the Global T-Cell Immunotherapy Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global T-Cell Immunotherapy Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global T-Cell Immunotherapy Market?
4. What is the competitive strategic window for opportunities in the Global T-Cell Immunotherapy Market?
5. What are the technology trends and regulatory frameworks in the Global T-Cell Immunotherapy Market?
6. What are the modes and strategic moves considered suitable for entering the Global T-Cell Immunotherapy Market?
Read the full report: https://www.reportlinker.com/p06007640/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001